Back

Diagnostic and prognostic significance of pericardial fluid biomarkers and a novel tumor-inflammation index in patients undergoing pericardiocentesis

28 August 2026 (13:15 - 14:00)
Organised by: Logo
Congress Presentation Part of: Advancing understanding in pericardial disease Pericardial Effusion ESC2026 Premium Access ESC Congress 2026 European Society of Cardiology

About the speaker

Photo
Doctor Cem Korucu

Suruc State Hospital, Sanliurfa (Turkiye)

6 More presentations in this session

Presentation thumbnail
Independent prognostic value of pericardial fluid lactate dehydrogenase beyond malignancy in patients undergoing pericardiocentesis: a multicenter registry study
Doctor J. Ahn (Changwon, KR)
Presentation thumbnail
Nationwide outcomes after first-time pericarditis: recurrence, rehospitalization, and mortality in a danish registry cohort
Doctor R. Stokholm Baekgaard (Copenhagen, DK)
Abstract Slides Video
Presentation thumbnail
Real-world performance of postpericardiotomy syndrome diagnostic criteria – an analysis of the prospective CAREBANK database
Miss N. Vasarainen (FI)
Abstract Slides Video
Presentation thumbnail
Association of etiology of pericardial fluid with mortality
Mr A. Kane (Rochester, US)
Abstract Slides Video
Presentation thumbnail
Predictors of hospitalization and early emergency department revisit in patients with pericardial syndromes: the PES-ED Study
Doctor L. Pelagatti (Florence, IT)
Abstract Slides Video

Access the full session

Session thumbnail
Advancing understanding in pericardial disease

The Event

Event poster

ESC Congress 2026

28 August 2026 13:15 CET
You may be interested in
thumbnail
Congress Presentation
Evolution of pericardial effusion in cancer patients
21 May 2023
thumbnail
Congress Presentation
Prognostic value of vascular inflammation biomarkers over clinical risk factors for cardiovascular risk : a meta-analysis
17 April 2021
thumbnail
Congress Presentation
CA-125 variation in acute Heart Failure
29 June 2021
thumbnail
Congress Presentation
Interleukin-6 as a potential biomarker of cancer therapy-related cardiac dysfunction: A comparative analysis with myeloperoxidase and tumor necrosis factor-alpha.
21 June 2025

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources

ESC 365 is supported by

novartis Explore sponsored resources
novo-nordisk Explore sponsored resources